Morgan Stanley analyst Aisyah Noor maintained a Hold rating on Tecan Group AG today and set a price target of CHF168.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aisyah Noor’s rating is based on a combination of factors that present both opportunities and challenges for Tecan Group AG. The company has shown positive order improvements in the third quarter compared to the second quarter, with their largest customer performing at the upper end of guidance. Additionally, the pharmaceutical sector and US activities are maintaining strong performance, which supports the company’s outlook.
However, there are concerns that have led to the Hold rating. The performance in China is not meeting expectations, and there is a delay in order fulfillment to 2026 due to tariffs affecting the Synergence segment. Moreover, the foreign exchange impact on the fiscal year’s margin is stronger than anticipated, affecting profitability. These mixed signals suggest that while there is potential for recovery, caution is warranted in the short term.
Noor covers the Healthcare sector, focusing on stocks such as Qiagen, bioMerieux, and DiaSorin S.p.A.. According to TipRanks, Noor has an average return of 6.3% and a 62.07% success rate on recommended stocks.